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ABSTRACT 
The overall survival rate for patients diagnosed with lung cancer is still extremely 
low and many affected patients are not eligible for first-line treatments such as 
surgery, chemotherapy, and radiation for the treatment due to the severe side effects 
associated with these therapies. Paclitaxel (PTX) along with imatinib mesylate are 
currently first-line therapies for many types of cancer (Kelly 2001, Schiller 2002). 
However, the successful delivery of paclitaxel faces many challenges due to its 
lipophilic nature and high protein affinity, which often results in low bioavailability. 
Solubilization of drugs such as PTX, enhanced tumor accumulation, and toxicity 
attenuation of such therapeutics can be enhanced via targeted delivery to tumors using 
nanoparticles (NPs). For example, chemotherapeutic drugs such as PTX and 
doxorubicin have been encapsulated singularly in micelles (Jinhyang 2012) and 
nanoliposomes (Zhang 2011), thereby increasing the efficacy of radiation therapy 
against in vitro lung cancer cells and in animals, demonstrating the success of 
nanoparticle-mediated treatment of cancer. Current cancer treatment, however, 
revolves around the tandem delivery of PTX and therapeutics such as imatinib, 
doxorubicin, and carboplatin. Unfortunately, multi-drug delivery is not easily achieved 
with single-agent delivery systems demonstrating the need for a nanoparticle system 
capable of delivering multiple drugs in tandem directly to the tumor site(s).  
While the enhanced permeability and retention (EPR) effect has served as a key 
rationale for using nanoparticles to treat solid tumors, as it allows for increased uptake 
of NPs at the tumor site, it often does not enable uniform delivery of these particles to 
all regions of tumors. Tumor-penetrating peptides show great promise in overcoming 
  
 
 
the relevant physiological barriers preventing accumulation and penetrating into the 
avascular region of tumors. iRGD (internalizing RGD, CRGDKDPDC), has been 
shown to effectively target and penetrate both in vitro multicellular spheroids (MCS) 
and in vivo animal model tumors when conjugated to drugs or nanoparticles (Sugahara 
2010). For the described research, I hypothesize that iRGD-conjugated nanoparticles 
containing PTX and imatinib will more effectively home to and penetrate lung cancer 
tumor spheroids for more effective treatment of this dismal disease. 
In particular, acetalated dextran (Ac-Dex) nanoparticles were synthesized to 
contain PTX and/or imatinib. These particles were shown to have sizes appropriate for 
systemic delivery (approximately 250 nm) and exhibited smooth, round morphology. 
All particle systems exhibited favorable homogeneity as evidenced by low 
polydispersity index values (less than 0.20) and were nearly neutral in charge with 
zeta potentials near zero. Both PTX and imatinib were successfully loaded into the 
nanoparticles with 50 and 14 weight % loading, respectively. 80% of iRGD was 
conjugated to the nanoparticles and the peptide showed affinity for A549 lung 
adenocarcinoma cells in vitro. A549 multicellular spheroids were generated to allow 
for evaluation of the newly developed therapeutics. Finally, in vitro analysis using 
A549 cells showed that the drug-loaded nanoparticles were more effective at killing 
cells than pure drugs. Overall, this work shows the promise of Ac-Dex drug-loaded 
nanoparticles conjugated with iRGD to enhance the treatment of lung cancer. 
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CHAPTER 1 
INTRODUCTION 
1.1  Background and Treatment of Lung Cancer 
The optimization and improvement of cancer therapeutics is currently an 
important objective of pharmaceutical research since there are still many problems 
faced in the treatment of many types of cancer including lung, glioblastoma, and 
pancreatic cancers, which have extremely poor treatment success rates (Sneed 1998). 
Therefore, the improvement of cancer treatment options through methods such as 
targeting and controlled release of therapeutic agents is in great need. 
Lung cancer is the second most commonly diagnosed cancer and the most fatal of 
all types of cancers, accounting for about one out of five malignancies in men and one 
out of nine malignancies in women (NCI 2014). There are two major types of lung 
cancer: small cell lung cancer (SCLC), which is also called oat cell cancer because the 
cells resemble oat grains, and non-small cell lung cancer (NSCLC). The 
aggressiveness of this disease and treatment options depend on the type and stage of 
cancer diagnosed. Available treatment options might include surgical resection, 
chemotherapy, and/or radiation. Since many types of lung cancer grow quickly and 
spread rapidly, and because the lungs are vital organs, early detection and prompt 
treatment (usually involving an initial surgery to remove the tumor) is critical to 
ensure increased patient survivability.  
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The majority of lung cancers are classified as non-small cell lung cancer, where 
about half of these are squamous cell carcinomas (SCC). SCC, sometimes called 
epidermoid carcinoma, is more prevalent in men and arises in the lining of the large 
air passageways or bronchi. Another common type of NSCLC is adenocarcinoma, 
which occurs at the outer edges of the lung. A small percentage of NSCLC are 
large-cell carcinomas, which usually develop in the smaller bronchi. Non-small cell 
lung cancer that begins at the top of the lung sometimes spreads to the nerves and 
blood vessels leading to the arm. All three subtypes of NSCLC develop differently and 
treatment options are often based on the location of the particular cancer and its rate of 
spread (NCI 2014). 
Early diagnosis and intervention can improve the survivability of patients 
diagnosed with lung cancer. Minimally invasive treatments such as video-assisted 
thoracoscopy and thoracotomy surgery (VATS) and radiofrequency ablation (RFA) 
can be used for the detection of lung cancer in its early stages. Comprehensive 
multi-modality treatment with a combination of local and systemic therapy can 
maximize the treatment outcome for more advanced-stage lung cancers. These 
therapies can include chemotherapy, targeted therapy, and rehabilitation. 
The five-year survival rates for patients diagnosed with non-small cell lung cancer 
who are eligible to undergo treatment can be found in Table 1. As seen in this figure, 
even patients who are diagnosed with Stage 1 NSCLC have only a 54% rate of 
survival after five years. This is often because even though patients diagnosed with 
Stage 1 cancer tolerate and survive their first round of treatment well, recurrences of  
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Table 1: Five-year survival rates of patients diagnosed with non-small cell 
lung cancer (NSCLC) (NCI 2014). 
 
Stage 5 Year Survival Rate 
0 Too few cases to evaluate 
I 54% 
II 35% 
IIIA 10 - 15% 
IIIB < 5% 
IV < 2% 
 
 
 
 
 
 4 
 
the disease are common and more aggressive. Unfortunately, very few patients with 
Stages IIIB or V NCSLS will be alive five years after their initial diagnosis. These 
dismal statistics show the importance in improved treatment options for patients 
diagnosed with NSCLC throughout the course of their disease.  
Surgical resection is the standard of care for early stage lung cancer, however, 
only 25% of patients have resectable disease at the time of diagnosis (Wisnivesky 
2005). This can be attributed to the poor health of patients diagnosed with NSCLC as 
many of these patients are former smokers with other severe health issues such as 
chronic obstructive pulmonary disease (COPD) and heart disease. In addition, these 
patients are often of an advanced age, indicating that they are often not healthy enough 
to undergo aggressive cancer treatments.  
In regards to chemotherapeutics, there are several drug classes used in 
combination with one another as the first-line therapies for many types of NSCLC 
(Kelly 2001, Schiller 2002). Of these drugs, there are many FDA-approved 
compounds currently used clinically for the treatment of NSCLC including paclitaxel 
(Jinhyang 2012) and cisplatin (Zhang 2011). In addition, there are many drugs under 
investigation for the treatment of NSCLC such as imatinib (Zhang 2003), everolimus 
(Kochanski 2012), and artesunate (Zhao 2011). While these particular drugs are not 
yet widely used in the treatment of NSCLC, they are currently approved for the 
treatment of other types of cancer. 
The ability of chemotherapeutics to kill cancer cells depends on their ability to 
halt cell division. Usually, these types of drugs work by damaging the RNA or DNA 
that tells the cell how to copy itself in division (Vermeulen 2003). If the cells are 
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unable to divide, they subsequently die. The faster the cells are able to divide, the 
more likely it is that chemotherapy will kill these cells, causing the tumor to shrink. 
This is the main tenant behind how chemotherapeutics work in that they attack rapidly 
growing cancer cells while sparing the majority of the body’s healthy tissues. 
However, this means that these therapeutics will also attack rapidly growing cells in 
other parts of the body including hair follicles and gastrointestinal tract.  
Chemotherapeutics ultimately induce apoptosis (self-death or cell suicide). Drugs 
that disrupt mitotic progression, which are commonly referred to as antimitotics, are 
used extensively for the treatment of cancer. Paclitaxel (Taxol®, Bristol-Myers 
Squibb Co., Princeton, New Jersey), which belongs to this class of chemotherapy 
drugs (Marupudi 2007), was originally derived from the bark of Taxus brevifolia 
(pacific yew tree). The structure of PTX can be seen in Figure 1. PTX binds to 
polymerized tubulin in cells, thereby preventing microtubule formation and promoting 
microtubule stabilization against disassembly. This in turn inhibits mitosis, and 
therefore prevents cancer growth.  
Imatinib mesylate (also known as simply imatinib, STI571, or Gleevec from 
Novartis Pharmaceutical Inc.), is a recently FDA-approved drug used for the treatment 
of chronic myelogenous leukemia and gastrointestinal stromal tumors. The structure of 
imatinib can be seen in Figure 2. Imatinib is an adenosine triphosphate (ATP) 
analogue, and it competitively binds to and inhibits the oncogene BCR-ABL tyrosine 
kinase, which results from the chromosomal translocation (Zhang 2003). While 
traditional cytotoxic cancer treatments such as chemotherapy or radiation therapy kill 
all dividing cells, imatinib acts on a molecular target by a mechanism that is more  
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Figure 1: Schematic of the chemical structure of paclitaxel (PTX). 
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Figure 2: Schematic of the chemical structure of imatinib mesylate (IM). 
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specific to cancer cells (Timeus 2012). Therefore, it is advantageous to use imatinib 
for the treatment of cancer because it is more specific to damaging cancer cells, 
thereby sparing healthy tissue. In particular, imatinib mesylate (IM) has been 
demonstrated to inhibit the growth and proliferation of gastrointestinal stromal tumors 
(GIST), and to induce the complete or partial clinical remission in GIST patients. In 
addition, IM was showed to inhibit the growth of dermatofibrosarcoma protuberans 
(DFSP) through inhibiting the platelet-derived growth factor (PDGF) receptor (Zhang 
2003). Despite encouraging pre-clinical data, IM has had limited clinical efficacy 
against neuroblastoma tumors when used as a single agent. In regards to lung cancer, 
it has been demonstrated that A549 cells overexpress PDGF receptor alpha (PDGFR 
α), one of the known potential targets for imatinib. The inhibitory effect of imatinib on 
A549 cells is likely mediated through inhibition of this receptor via phosphorylation 
(Zhang 2003). Overall, these results show the promise that IM has to selectively target 
and treat a wide variety of tumors. 
Despite the widespread use of the aforementioned therapeutics for the treatment 
of cancer, as with other types of chemotherapeutics, they often face challenges in 
therapeutic efficacy due to limitations in systemic delivery. In particular, the delivery 
of paclitaxel faces many challenges due to its lipophilic nature and high protein 
affinity, which ultimately results in low bioavailability due to its very minimal 
solubility in water. Also, while the addition of Cremophor EL (a type of 
polyethoxylated castor oil) and ethanol in the intravenous Taxol® formulation is used 
to increase the solubility of PTX, these additives often cause severe side effects in 
many patients (Carvalho 2011).  
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It has been shown that drug solubilization, an increase in tumor accumulation, and 
toxicity attenuation of drugs can be enhanced via the use of nanoparticles for the 
delivery of anti-cancer agents. For example, single-agent paclitaxel plays a central role 
in the treatment of advanced NSCLC. As mentioned previously, the use of this drug is 
limited, however, by its poor solubility and by the toxicities associated with additives 
in the formulation Taxol®. Abraxane is an FDA-approved therapeutic that is 
comprised of a paclitaxel protein (albumin)-bound nanoparticle system delivered to 
patients via an injectable suspension. These nanoparticles were developed by 
American BioScience, Inc. (Santa Monica, California) and are Cremophor EL- and 
ethanol-free. That nanoparticles are approximately 130 nm size and have been 
designed to address the solubility limitations of traditional paclitaxel (Green 2006).  
In addition, paclitaxel-loaded poly(ethylene glycol) and poly(lactic-co-glycolic 
acid) (PLGA)-based nanoparticles have been developed where this new system is 
more cytotoxic on Hela cells than Taxol® (Goodman 2008). In contrast to Cremophor 
EL, no cytotoxicity of the polymers that make up these nanoparticles was observed 
(Danhier 2009). In regards to IM, imatinib mesylate has also been successfully loaded 
into PEG-PLGA nanoparticles as an model system for successful intracellular delivery 
of molecular targeting drugs in excised veins (Kimura 2008). Similarly, imatinib 
mesylate-chitosan poly(ε-caprolactone) (PCL) nanoparticles have been investigated 
for their potential in enhancing controlled release and improving chemotherapeutic 
efficiency of IM (Cortese 2014). In regards to tandem delivery vehicles, dual-drug 
loaded nanoparticles containing PTX and gemcitabine have been used against human 
pancreatic cancer cells and their cytotoxicity was significantly improved compared to 
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the free drugs (Aryal 2010). A study from the Acharya lab demonstrated that 
dual-drug loaded nanoparticles work in a synergistic manner lowering the dose of 
administration and time of action of the drugs, ensuring that both drugs reach the 
targeted cells specifically and maximize cytotoxicity while minimizing the chances of 
cell resistance to any one drug (Acharya 2011). Current treatment, however, revolves 
around the combined delivery of multiple therapeutics, and this is not easily achieved 
with single-agent nanoparticle systems demonstrating the need for a therapeutic 
capable of tandem delivery of chemotherapeutics. Overall, these studies show the 
feasibility in using drug-loaded nanoparticles to enhance the treatment potential of 
currently available anticancer therapeutics. 
 
1.2 Nanoparticle-Based Drug Delivery Platforms and the Use of 
Tumor-Penetrating Peptides 
There are currently many drug delivery systems in development for the treatment 
of lung cancer and some of them have achieved moderate progress and have brought 
about the considerable development in this area of research. In fact, several targeted 
drug and gene delivery systems have been developed to treat NSCLC more effectively. 
For example, Sundaram et al. developed a conjugate drug system containing deslorelin 
(an anti-angiogenic compound) and docetaxel (a traditional chemotherapeutic 
compound) where the drugs were conjugated with the peptide RGD and delivered in 
vivo (Sundaram 2009). The in vitro and in vivo efficacy of these peptide-conjugated 
drugs were evaluated in H1299 (NSCLC) cells and xenografts in athymic nude mice 
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and the results showed that the conjugated peptide enhanced both the in vitro and in 
vivo efficacies significantly.   
Nowadays, much attention is being focused on nanotechnology, where this refers 
to the interactions of molecular components and engineered materials at the nanoscale. 
Nanomaterials are typically clusters of atoms, molecules, and molecular fragments 
formed into incredibly small particulates. Nanometer-sized particles have novel 
optical, electronic, and structural properties that are not always present in individual 
molecules or bulk solids (Sajja 2009). The concept of nanoscale devices has led to the 
development of biodegradable self-assembled nanoparticles, which have been 
engineered for the targeted delivery of anticancer drugs and imaging contrast agents. 
Nanoconstructs such as these can serve as customizable, targeted drug delivery 
vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic 
genes into malignant cells while sparing healthy cells. Such ‘‘smart’’ multifunctional 
nanodevices hold out the possibility of radically changing the practice of oncology, 
allowing easy detection and then followed by effective targeted therapeutics at the 
earliest stages of the disease (Sinha 2006). In particular, polymeric nanoparticles 
(PNPs) are defined as particulate dispersions or solid particles with size in the range of 
10 - 1000 nm. There has been considerable research interest in the area of drug 
delivery using particulate delivery systems as carriers for small and large molecules.  
 The techniques for the preparation of nanoparticles depend on the particular 
application and or drug to be loaded into the nanoparticle system. A mini-review of 
several common methods for the preparation of nanoparticles from dispersions of 
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preformed polymer can be seen in Table 2 and methods for preparation of 
nanoparticles from polymerization of monomers in Table 3. 
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Table 2: Review of the common methods used for the preparation of 
nanoparticles. 
 
Preparation Method Preparation Details 
Solvent evaporation Solvent evaporation was the first method 
developed to prepare PNPs. In this method, polymer 
solutions are prepared in volatile organic solvents and 
vigorously mixed with aqueous solutions so that 
emulsions are formulated. This emulsion is converted 
into a nanoparticle suspension upon evaporation of the 
solvent from the polymer, which is allowed to diffuse 
through the continuous phase of the emulsion.  
Nanoprecipitation Nanoprecipitation is also called the solvent 
displacement method. It involves the precipitation of a 
preformed polymer from an organic solution and the 
diffusion of this organic solvent into the aqueous 
medium in the presence or absence of a surfactant 
(Fessi 1989, Barichello 1999, Galindo-Rodriguez 2004, 
Ganachaud 2005) . 
Emulsification/solvent 
diffusion 
This method is a modified version of solvent 
evaporation method. The encapsulating polymer is 
dissolved into a partially water soluble solvent such as 
 14 
 
propylene carbonate and saturated with water to ensure 
the initial thermodynamic equilibrium of both liquids. 
To produce the precipitation of the polymer and the 
consequent formation of nanoparticles, it is necessary 
to promote the diffusion of the solvent of the dispersed 
phase by dilution with an excess of water when the 
organic solvent is partly miscible with water or with 
another organic solvent in the opposite case. 
Subsequently, the polymer-water saturated solvent 
phase is emulsified in an aqueous solution containing a 
stabilizer, leading to solvent diffusion to the external 
phase and the formation of nanoparticles, according to 
the oil-to-polymer ratio. Finally, the solvent is 
eliminated by evaporation or filtration, according to its 
boiling point (Niwa 1993). 
Salting out The salting out method is based on the separation 
of a water miscible solvent from aqueous solution via a 
salting out effect. The salting out procedure can be 
considered as a modification of the 
emulsification/solvent diffusion (Fessi 1989, Jeon 2000,  
Jeong 2001, Kostag 2010, Rao 2011) . 
Dialysis Dialysis offers a simple and effective method for 
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the preparation of small, narrow-distributed PNP. A 
polymer is dissolved in an organic solvent and placed 
inside a dialysis tube with proper molecular weight cut 
off. Dialysis is performed against a non-solvent 
miscible with the former miscible. The displacement of 
the solvent inside the membrane is followed by the 
progressive aggregation of polymer due to a loss of 
solubility and the formation of homogeneous 
suspensions of nanoparticles (York 1999, Kawashima 
2001, Rao 2011). 
Supercritical fluid 
technology (SCF) 
The need to develop environmentally safer 
methods for the production of PNP has motivated 
research on the utility of supercritical fluids as more 
environmental friendly solvents, with the potential to 
produce PNPs with high purity and without any trace of 
organic solvent. Supercritical fluid and dense gas 
technology are expected to offer an interesting and 
effective technique of particle production, avoiding 
most of the drawbacks of the traditional methods. Two 
principles have been developed for the production of 
nanoparticles using supercritical fluids: 1) Rapid 
expansion of supercritical solution (RESS) and 2)  
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Rapid expansion of supercritical solution into liquid 
solvent (RESOLV) (York 1999, Kawashima 2001, Rao 
2011). 
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Table 3: Overview of the methods used for the preparation of nanoparticles 
from the direct polymerization of monomers. 
 
Preparation Method Preparation Details 
Emulsion Emulsion polymerization is one of the fastest 
methods for nanoparticle preparation and is readily 
scalable. The method is classified into two categories, 
based on the use of an organic or aqueous continuous 
phase. The continuous organic phase methodology 
involves the dispersion of monomer into an emulsion or 
inverse microemulsion, or into a material in which the 
monomer is not soluble (non-solvent). Polyacrylamide 
nanospheres were produced by this method. As one of 
the first methods for production of nanoparticles, 
surfactants or protective soluble polymers have been 
used to prevent aggregation in the early stages of 
polymerization (Pinto Reis 2006). 
Interfacial 
polymerization 
This method involves step polymerization of two 
reactive monomers or agents, which are dissolved 
respectively in two phases (i.e., continuous- and 
dispersed-phases). A reaction takes place at the 
interface of the two liquids to form nanoparticles in 
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suspension. (Lambert 2000, Charcosset 2006, Gaudin 
2008, Wu 2009, Landfester 2010)  
Controlled/Living 
radical polymerization 
(C/LRP) 
Weak intramolecular interactions among polymer 
chains can be exploited to form organized 
nanostructured materials, provided the polymers have 
uniform dimensions, topologies, compositions and 
functionalities. Particular emphasis is placed on 
structure–reactivity correlations and ‘‘rules’’ for catalyst 
selection in atom transfer radical polymerization 
(ATRP), for chain transfer agent selection in reversible 
addition-fragmentation chain transfer (RAFT) 
polymerization, and for the selection of an appropriate 
mediating agent in stable free radical polymerization 
(SFRP), including organic and transition metal 
persistent radicals (Braunecker 2007). 
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With the increased use of nanoparticles for drug delivery applications, it has been 
noted that there are many advantages in using these systems over traditional 
systemically delivered pure drug systems (Kayser 2005, Abhilash 2010). Such 
advantages in the use of polymeric nanoparticle systems include, but are not limited to 
the following: 
 
 The increased stability of any volatile pharmaceutical agents present. 
 The fabrication of large quantities of particles is easy and cheaply done using a 
multitude of methods. 
 A significant improvement over traditional oral and intravenous methods of 
administration in terms of efficiency and efficacy is often seen. 
 There is delivery of a higher concentration of a pharmaceutical agent to a 
desired location. 
 Modified drug release allows for tailoring of drug delivery. 
 They can be applied to a wide variety of drug delivery fields including cancer 
therapy, delivery of vaccines, contraceptives, and targeted antibiotics. 
 The can be easily incorporated into other activities related to drug delivery, 
including tissue engineering. 
 
The enhanced permeability and retention (EPR) effect involves the extravasation 
of nanoparticles from “leaky” tumor vasculature into tumor tissue. While the EPR 
effect has served as the key rationale for using nanoparticles to treat solid tumors, it 
often does not enable uniform delivery of these particles to all regions of tumor. 
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Furthermore, while ligands that target cancer cells can often increase the intracellular 
concentration and cytotoxicity of targeted nanoparticles, the intratumoral penetration 
is not improved significantly compared with non-targeted nanoparticles (Jain 2010). 
This is due to multiple factors including ineffective targeting ligands, the tumor-blood 
vessel wall barrier, slow diffusion into the interstitium of tumors, and physiological 
barriers of the tumor. These barriers include the lack of functional lymphatic vessels, 
elevated interstitial fluid pressure, and dense extracellular matrix (Jain 1990).  
 Tumor-penetrating peptides show great promise in overcoming many barriers that 
prevent the accumulation and penetration of nanoparticles into the avascular region of 
tumors. iRGD (internalizing RGD, CRGDKDPDC), a cyclic peptide, has been shown 
to effectively target and penetrate both in vitro three-dimensional multicellular 
spheroids and in vivo animal model tumors when conjugated to drugs or nanoparticles 
(Sugahara 2010). The peptide iRGD initially accumulates at the surface of αν 
integrin-expressing cells and tissue in tumors. This is advantageous in that integrins 
are overexpressed in many types of tumors and tumor-associated vasculature and 
tissue while being minimally expressed in healthy tissue (Waite 2009, Desgrosellier 
2010). Once iRGD reaches the integrin target, it is cleaved by cell surface-associated 
proteases to expose the C terminus and CandR element which then mediates binding 
to neuropilin-1, resulting in penetration of the cancerous cells and tissues as seen in 
Figure 3. iRGD has been used effectively with many new and already FDA-approved 
nanoparticle systems and drugs such as doxorubicin, Abraxane®, Doxil® and 
trastuzumab to enhance tumor penetration and treatment efficacy in in vivo models 
(Sugahara 2009). In addition, it enhances tumor penetration when co-administered 
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Figure 3: Illustration of iRGD-conjugated acetalated dextran (Ac-Dex) 
nanoparticles developed in this research where A) depicts the peptide cleavage 
and penetration mechanism of the iRGD peptide and B) depicts tumor tissue 
penetration by the nanoparticles due to the presence of iRGD. 
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with drugs and particles. 
The contribution of the therapeutic nanoparticle systems developed in this current 
research lies in the production of a system that will be easier to deliver to patients by 
combining multiple agents into one platform. Furthermore, it will allow not only for 
the direct targeting of anticancer agents to lung tumors but will induce penetration of 
the nanoparticle into tumor tissue, which can potentially allow for a lower dose of the 
drugs to be used due to increased specificity (Simberg 2007, Karmali 2009, Ruoslahti 
2010). The potential to lower the dosage of chemotherapeutic drugs using a 
nanoparticle drug delivery system could result in a treatment that is both safer for 
patients and easier to tolerate, especially for those that are not ideal candidates for 
aggressive treatment. 
 Both the elderly and patients with morbidities such as chronic obstructive 
pulmonary disease (COPD) could benefit greatly from this type of treatment since 
they are usually neither eligible for surgery nor healthy enough for chemotherapy 
(Schroedl 2012). Since 50 - 80% of lung cancer patients have COPD (Young 2009), 
there is a significant portion of the population that could benefit from a more targeted, 
safer treatment option.   
 
1.3 Multicellular Spheroids (MCS) in Cancer Treatment Evaluation 
 Determining whether or not nanoparticles will penetrate the tumor 
microenvironment is often difficult and while cell uptake studies are most commonly 
used to show this potential, they bear minimal physiological resemblance to tumors. 
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Conventional two-dimensional (2D) cell culture techniques have been utilized for 
decades to test the efficacy of anti-cancer therapeutics despite limited translation of 
the given results into in vivo models. The use of three-dimensional (3D) muticellular 
tumor spheroids (MCS) have been used to overcome these limitations. 3D MCS are 
clusters of cells that compact to form tight spheroids in vitro when cell-to-cell 
interactions dominate over cell-to-substrate interactions, as seen in Figure 4. These 
systems are advantageous in vitro models as they are vastly different from monolayer 
cultures with respect to gene activation, antigen expression, and growth (Ingram 
2010).  
MCS can mimic avascular in vivo tumors in that they have diffusion limitations 
for many molecules, including oxygen, and this inefficient mass transport leads to 
metabolic waste accumulation inside the MCS so that they display a layer-like 
structure comprised of a necrotic core surrounded by a viable rim of cells (Lin 2008). 
It is usually the center of tumors that exhibit a hostile microenvironmrnt, as these 
regions harbor the most aggressive tumor cells, which will regenerate if they are not 
eliminated. MCS have been effectively used to study many types of therapeutics 
including nanoparticles, chemotherapeutics, and radiation where the MCS show 
significant differences in reponse in comparison to 2D cell monolayers (Goodman 
2007, Goodman 2008). This illustrates imparts the importance of these systems in 
optimizing drug and nanoparticle systems for systemic delivery to tumors.  
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Figure 4: Schematic depicting the formation of spheroids for loose cell aggregates 
into a compact spheroid following a brief delay period in formation. 
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1.4 Acetalated Dextran (Ac-Dex) as a Novel Drug Delivery Platform
 Acetalated dextran (Ac-Dex) is a newly developed polymer in which pendant 
acetal groups are reacted onto hydroxyl groups present on the backbone of dextran to 
give this polymeric compound unique characteristics. The reaction of dextran with 
2-methoxypropene leads to the formation of both cyclic and acyclic acetals, causing a 
switch in solubility and providing a trigger for acid-mediated degradation (Broaders 
2009). Cyclic and acyclic acetals have completely different rates of hydrolysis (Fife 
1965) and the amount of each present can be tailored by the extent of reaction 
allowing for the modulation of degradation rates from hour to weeks (Meenach 2012).  
In addition to allowing for tunable degradation, Ac-Dex has solubility properties 
opposite of those of parent dextran, namely that it is soluble in organic solvents and 
insoluble in water allowing for the processing of Ac-Dex into nanoparticles via 
standard emulsion techniques (Bachelder 2008). Furthermore, Ac-Dex has pH neutral 
degradation by-products (parent dextran and small amount of acetone and methanol) 
and is acid sensitive. At low pH Ac-Dex degradation occurs more quickly whereas at 
higher pH, the polymer degrades more slowly. In vitro assays have indicated that 
Ac-Dex and its degradation by-products are as safe as the FDA-approved polymer 
poly(lactic-co-glycolic acid) (PLGA) (Bachelder 2008), which is commonly used in 
polymeric nanoparticle formulations. The use of Ac-Dex for the tandem delivery of 
agents significantly advances the development of a targeted biodegradable nanocarrier 
in that the carrier can be made to degrade fully within a day or up to a week without 
harmful polymer accumulation or degradation by-products. Thus far, Ac-Dex has been 
used in particle formulations for applications in immunology/vaccines (Broaders 2009, 
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Kauffman 2011), tumor targeting (Beaudette 2009), improved storage of therapeutics 
(Kanthamneni 2012), and pulmonary therapeutics (Meenach 2012). 
 
1.5 Research Aims and Objectives 
The overall aim of this project was to develop and optimize acetalated 
dextran-based peptide-conjugated polymer nanoparticles, which can deliver 
anti-cancer agents in tandem to allow for enhanced targeting and treatment of 
non-small cell lung cancer. The specific research for this project include: 
 To synthesize acetalated dextran-based iRGD-conjugated nanoparticles loaded 
with paclitaxel and/or imatinib mesylate. 
 To evaluate and optimize the physicochemical properties the 
peptide-conjugated Ac-Dex nanoparticles. 
 To assess the efficiency of the proposed nanoparticle system in the treatment 
of non-small cell lung cancer using in vitro methods. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials 
Phosphate buffered saline (PBS), resazurin (sodium salt, pure, high purity 
biological stain), glycine, Dulbecco’s Modified Eagle Medium (DMEM), and 
Fungizone® were obtained from Fisher Scientific (Kansas City, MO, USA). Paclitaxel 
was obtained from LC Labs (Woburn, MA, USA; 99.5% purity). Tween 20, 
Kolliphore EL (previously known as Cremophor EL), dextran (average molecular 
weight 9,000 - 11,000), dimethyl sulfoxide (DMSO, ≥ 99.9%), poly(vinyl-alcohol) 
(PVA, MW 13,000 - 23,000), pyridinium p-toluenesulfonate (PPTS, 98%), fluorescein 
isothiocyanate (FITC, HPLC grade, ≥ 90%), 2-methoxypropene, deuterium oxide 
(D2O), deuterium chloride solution (DCl), dichloromethane (DCM, ≥ 98%), 
triethylamine (TEA), methanol (HPLC grade, ≥ 99.9%), acetone (HPLC grade, ≥ 
99.9%), acetonitrile (HPLC grade, ≥ 99.9%), and fetal bovine serum (FBS) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Imatinib mesylate (Imatinib or 
IM) was purchased from Adipogen International, Inc. (San Diego, CA, USA). 
Lysotracker red, calcein AM, ethidium homodimer-1 (EthD-1), sodium pyruvate, and 
Pen-Strep were purchased from Life Technologies (Carlsbad, CA, USA). Collagen (rat 
tail type Ι) was obtained from Discovery Labware, Inc. (Two Oak Park, Bedford, MA, 
USA). Poly(2-hydroxyethyl methacrylate) (pHEMA) was obtained from Polysciences, 
Inc. (Warrington, PA, USA). Vectashield hardset mounting media with 
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4',6-diamidino-2-phenylindole (DAPI) was obtained from Vector Labs, Inc. 
(Burlingame, CA, USA). All materials were stored in the conditions recommended by 
the manufacturer and were used as received.  
 
2.2 Synthesis and Characterization of Acetalated Dextran (Ac-Dex) 
 Ac-Dex was synthesized by the reaction of dextran with 2-methoxypropene as 
seen in Figure 5. 1 g of lyophilized dextran (9,000 - 11,000 MW) was mixed well with 
15.5 mg pyridinium p-toluenesulfonate in 10 mL of anhydrous DMSO to allow for 
complete dissolution of the dry components. The reaction was initiated by adding 1 
mL of 2-methyoxypropene, which added the acetal groups (both cyclic and acyclic) to 
the parent dextran. The reaction proceeded for five minutes to produce fast degrading 
Ac-Dex (Bachelder 2008, Broaders 2009). The reaction was then quenched with 1 mL 
of triethylamine (TEA), followed by precipitation in basic water (pH 9.5), isolation via 
filtration, and lyophilization. Basic water was made by mixing TEA in deionized water 
for a final pH value of 9.5. This solution prevents the early degradation of 
pH-sensitive Ac-Dex. 
1
H-NMR analysis was performed to provide information on the relative cyclic to 
acyclic ratio of acetal groups of the newly synthesized Ac-Dex polymer. 10 mg of 
Ac-Dex was suspended in an NMR tube with 700 μL of D2O (deuterium oxide) and 30 
μL of DCl (deuterium chloride), where the DCl was used to facilitate fast degradation 
of the Ac-Dex in the solution. During the degradation of Ac-Dex, hydrolysis of one 
cyclic acetal produces one acetone molecule whereas hydrolysis of one acyclic acetal  
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Figure 5: Schematic showing the reaction for the synthesis of acetalated dextran 
(Ac-Dex). Dextran was reacted with 2-methoxypropene and a catalyst in DMSO 
to form acyclic and cyclic acetalated dextran. 
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produces one acetone and one methanol molecule. Therefore, from the relative ratio of 
the peaks from acetone, methanol, and the cyclic to acyclic ratio of acetal substitution 
and degrees of hydroxyl substitution per 100 glucose could be determined using 
1
H-NMR (Broaders 2009). The cyclic to acyclic acetal ratio will be further referred to 
as the CAC.  
2.3 Synthesis, Optimization, and Characterization of Drug-Loaded Ac-Dex 
Nanoparticles 
Single emulsion (water/organic or W/O) nanoparticle synthesis techniques using 
ultrasonic probe sonication were used to form particles loaded with paclitaxel (PTX) 
and imatinib mesylate (IM). The initial theoretical encapsulation efficiency for the 
nanoparticles was 0.1 weight % and 10 weight % for PTX- and IM-loaded 
nanoparticles, respectively. For PTX-loaded nanoparticles, 0.5 mg of PTX was 
dissolved into 1 mL of DMSO, which resulted in a concentration of 0.5 mg/mL. For 
Imatinib-loaded nanoparticles, 50 mg of PTX was dissolved into 1 mL of DMSO, 
which resulted in a concentration of 50 mg/mL.50 mg of Ac-Dex was then transferred 
to a 20 mL scintillation vial followed by 900 μL of dichloromethane and 100 μL of the 
drug/DMSO solution (0.5 mg/ml PTX in DMSO or 50 mg/mL Imatinib in DMSO), 
resulting in the final organic (O) solution. Then, 2 mL of 3 % w/v poly (vinyl alcohol) 
(PVA) in phosphate buffered saline (PBS), the aqueous phase (W), was added as to 
the organic solution and the vial was transferred to an ice bucket. The O and W 
solutions were sonicated for 30 seconds (QSonica Q500, 0.5 inch flat tip, amplitude of 
50 %, 1 second on/off pulse) and then the resulting emulsion was poured into a stirring 
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solution 40 mL of 0.3 % w/v PVA in PBS and stirred for four hours. After particle 
hardening and solvent evaporation, the solution containing the nanoparticles was 
centrifuged at 10,000 rpm (13,571 rcf) for 10 minutes.  
 After centrifugation, the supernatant solution was decanted and 1 mL of basic 
water (pH 9.5) was added to each tube. The resulting particle pellets were then 
resuspended in the basic water using a pipette and water bath sonication, as needed. 
The remainder of the tubes with the resuspended nanoparticles was filled with basic 
water and this centrifugation and washing step was repeated until the particles had 
been washed three times. After the final decantation, the particles were suspended in 1 
mL of basic water, and this solution was then transferred to a 5 mL tube. A further 3 
mL of basic water was used to rinse the centrifuge tubes and this wash solution was 
added to the 5 mL tube for a final volume of 5 mL. The particle solution was then put 
in the freezer for one hour followed by lyophilization for 24 hours. A schematic of this 
process can be found in Figure 6.  
   The mean size (diameter), polydispersity index (PDI), and zeta potential of the 
particles was determined using a Malvern Zetasizer Nano ZS capable of dynamic light 
scattering (DLS) and zeta potential measurement. The shape and surface morphology 
of particles was evaluated by scanning electron microscopy (SEM), using a Zeiss 
SIGMA VP Field Emission-Scanning Electron Microscope (FE-SEM). For SEM 
evaluation, samples were placed on aluminum stubs (TedPella, Inc., Redding, CA, 
USA) and were then coated with a gold/palladium alloy thin film using an Emscope 
SC400 sputter coating system at 20 mA for 30 seconds under argon gas. The electron  
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Figure 6: Schematic of nanoparticle synthesis via single emulsion/solvent 
evaporation method. 
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beam with an accelerating voltage of 5 to 10 kV was used at a working distance of 
13.3 to 15.3 mm. Images were captured at several magnifications. 
The encapsulation efficiency, drug loading, and drug release of PTX and IM 
loaded nanoparticle determined by dissolving the particles completely in acrylonitrile 
and methanol, respectively, and analyzing these results via Ultra Performance Liquid 
Chromatography (UPLC). PTX nanoparticles drug release behavior was analyzed by 
placing the particles in a physiologically buffered modified release medium (pH 7.4) 
containing PBS, 4 weight % Kolliphore EL, and 2.4 weight % Tween 20 to enhance 
the solubility of PTX upon release. Imatinib-loaded nanoparticles release behavior was 
analyzed by placing the particles in a physiologically buffered medium (pH 7.4). The 
release took place at 37°C and 100 rpm.  
UPLC was performed using a Hitachi analytical HPLC system with D-700 HPLC 
System Manager software for data analysis. The separation was achieved using an 
Ascentis® C-18 HPLC column (4.6 mm x 15 cm, 5 μm pore size). The mobile phase 
for paclitaxel detection consisted of acetonitrile and water (50:50 v/v) with a 20 μL 
injection volume and 1.0 ml/min mobile phase flow rate. The column eluate was 
evaluated at 227 nm for the detection of paclitaxel in the samples. The mobile phase 
for imatinib detection consisted of 50 volume % methanol and 50 volume % aqueous 
formic acid (0.5 volume % in water) with a 20 μL injection volume and 1.2 ml/min 
mobile phase flow rate. The column eluate was evaluated at 270 nm for the detection 
of IM in the samples. For both the PTX and IM evaluation, calibration curves (Figure 
A1 and Figure A2, respectively) were generated using UPLC as described above. 
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These calibration curves are present in Appendix A. From this analysis the 
encapsulation efficiency and drug loading of the nanoparticles were evaluated as: 
 
Encapsulation Efficiency =  
Actual Mass of Drug in Nanoparticles
Theoretical Mass of Drug in Nanoparticles
 x 100% 
 
Drug Loading =  
Actual Mass of Drug in Nanoparticles
Mass of Nanoparticles
 
 
Furthermore, the percent of drug released was evaluated from: 
 
Drug Release (%) =  
Mt
M∞
 
 
where Mt is the mass of the drug at time point (t) and M is the mass of drug in 
sample. 
Thermal analysis and phase transition measurements were carried out using a TA 
Q10 differential scanning calorimetry (DSC) system (TA Instruments, New Castle, 
DE, USA) with TA Instruments Explorer software and DSC refrigerated cooling 
accessory. 1 to 5 mg of sample was weighed into hermetic anodized aluminum DSC 
pans and was sealed hermetically sealed. Dry nitrogen gas was used as the purging gas 
at 50 mL/min. The heating range during DSC analysis was 0 to 300 °C at a heating 
scan rate of 10.00 °C/min. 
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2.4 In Vitro Biological Characterization  
Lung carcinoma (A549) cancer cells (obtained from American Type Culture 
Collection, Manassas, VA, USA) were evaluated for their response to the 
chemotherapeutic agents paclitaxel and imatinib. The base cell culture medium for the 
cell line was Dulbecco's Modified Eagle Medium (DMEM). The complete medium for 
cells contained DMEM with 10 % v/v fetal bovine serum (FBS), Pen-Strep (100 
I.U./ml penicillin, 100 μg/ml streptomycin), Fungizone® (0.5 µg/ml amphotericin B, 
0.41 µg/ml sodium deoxycholate), and 1 mM of sodium pyruvate. The cells were 
cultured at 37 °C and 5 % CO2 in a humidified incubator and were used from passages 
3 through 15. A549 cells were selected for the described research since these cells 
have been shown to overexpress v3 integrins (Odrljin 2001, Chetty 2010) and 
therefore iRGD should home to and penetrate into cells and spheroids composed of 
these cells (Sugahara 2009).  
Initially, for two-dimensional (2D) studies, A549 cells were seeded at 5,000 
cells/well with 100 μL/well in 96 well plates and were placed in an incubator for 24 
hours. For three-dimensional (3D) multicellular spheroid (MSC) cell studies, 96 round 
bottom well plates were coated with 0.5 % w/v poly(2-hydroxyethyl methacrylate) 
(pHEMA) in 200 proof ethanol and allowed to try for 48 hours. A549 cells were then 
seeded at 5,000 cells/well, 100 μL/well, and with 20 µg collagen/ml in the media in 
the coated round bottom 96 well plates. These plates were then centrifuged at 1500 rcf 
for 15 minutes and were placed in the incubator for 24 hours to facilitate spheroid 
compaction and formation. 
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The 2D cells and 3D spheroids were then exposed to the following conditions for 
48 hours: (i) raw PTX at 0.001, 0.01, 0.05, 0.1 0.5, 5 and 10 μM in complete medium 
with 0.1 volume % DMSO, (ii) 0.1% PTX-loaded nanoparticles at 0.001, 0.01, 0.05, 
0.1, 0.5 and 1 μM, where the PTX amount was calculated from the actual drug loading 
of the nanoparticles, (iii) raw imatinib at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 μM 
in complete medium with 0.1 volume % DMSO, and (iv) 10% imatinib-loaded 
nanoparticles at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, and 50 μM imatinib, where the IM 
amount was calculated from the actual drug loading of the nanoparticles. The controls 
for these studies were complete media with 0.1 volume % DMSO. The media 
solutions contained 0.1 % (v/v) DMSO to increase PTX and IM solubility and the 
DMSO control was used as a comparison to ensure no negative effects on the cells 
were due to the solvent. The solutions were all initially made with double the final 
concentration and 100 L of the solutions was added to each well already containing 
100 L of media. 
After 48 hours, a resazurin assay was used to assess the cell viability of the cells. 
Resazurin is converted to highly fluorescent resorufin by cells that are alive. 20 L of 
20 mM resazurin was added to each well containing cells and the well plates were 
incubated for 3 hours. After this time, the samples were evaluated using a multi-mode 
plate reader (Cytation 3, BioTek Instruments, Vermont, USA) at an excitation 
wavelength of 544 nm and emission wavelength of 590 nm with gains of 50, 70, and 
90. The relative viability of the cells was determined by the fluorescence intensity: 
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Relative viability (%) = 
Fluorescence Intensity of Sample
Fluorescence Intensity of Control
 𝑥 100%        
 
As seen above, these results were reported as the ratio of the fluorescence 
intensity of the resorufin generated from live cells for a given sample exposed to 
treatment in comparison to the fluorescence intensity generated from live cells not 
exposed to drug treatment. The inherent relative viability is thus a comparison in cell 
response to the given control. The corresponding half maximal inhibitory 
concentration (IC50) values for raw PTX, 0.1% PTX-loaded nanoparticles, raw 
imatinib, and 10% imatinib-loaded nanoparticles in the sample were determined using 
the four-parameter logistic equation and were subsequently fit to this equation using 
http://www.readerfit.com. The four-parameter logistic equation used to generate and 
fit the dose-response curves corresponding to the relative viability and drug 
concentration is defined as: 
 
𝑉 = 𝐷 +  
𝐴 − 𝐷
1 +  (
𝑥
𝐶)
𝐵 
 
where V is the relative viability, A is minimum viability of the cells at the highest 
tested drug concentration, B is the Hill’s slope of the dose-response curve, C is the 
IC50 value (evaluated at the inflection point of the slope), and D is the maximum 
viability of the cells not exposed to any therapeutics. The actual viability values were 
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graphed along with the theoretical fit values obtained from the four-parameter logistic 
equation. 
To evaluate the potential uptake of nanoparticles into lung cancer cells, A549 
cells were seeded at 125,000 cells/mL (300 μL/well) in 8 well chamber slides and 
were placed in an incubator for 24 hours to allow time for cell attachment. The cells 
were then exposed to 1 mg/mL of fluorescently-labeled drug-loaded nanoparticles in 
media for 24 hours at 37 °C. These nanoparticle systems were 0.1% PTX-loaded and 
10% imatinib-loaded nanoparticles with the addition of 2 weight % fluorescein 
isothiocyanate (FITC) added to the organic phase during nanoparticle synthesis to 
allow for fluorescent imaging of the particles. After the cells were exposed to the 
nanoparticle/media solutions (up to 24 hours), the particle solutions were removed and 
the cells were washed twice with 200 mM glycine to remove any unbound particles, 
followed by an additional wash with PBS. The cells were then stained with 750 nM 
Lysotracker Red and fixed with hardset Vectashield containing DAPI prior to imaging 
with a Nikon Eclipse E600 upright microscope. 
The ability of A549 cells to form spheroids and their growth with time was 
evaluated using brightfield microscopy (Nikon Diaphot TMD). The spheroids were 
imaged immediately after centrifugation and then each day for up to 5 days. The size 
of the spheroids was analyzed using ImageJ software (Abramoff 2004). 
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2.5 iRGD Conjugation and Tumor-Penetration Efficacy of Nanoparticles 
Two types of iRGD were used for the studies described in this research. The first 
type of iRGD was peptide with no fluorescent tag and extra cysteine (G) residues that 
was synthesized, purified (99 % purity), and characterized by Rakesh Tiwari, a 
collaborator in the Department of Biomedical and Pharmaceutical Sciences at the 
University of Rhode Island (Kingston, RI). The final compound 
(NH2-CGGGCRGDKGPDCG-CONH2) was an alkoxyamine-functionalized peptide 
that could be conjugated to Ac-Dex nanoparticles owing to the ability of 
polysaccharides to form stable oxime conjugates with alkoxyamine-bearing molecules 
(Beaudette 2009). The second type of iRGD use in the described studies was 
CRGDKGPDC labeled with a TAMRA fluorophore to allow for easy detection of the 
iRGD in solution. This compound was generously donated by Anastasia Kruse, a 
collaborator in the Department of Chemical Engineering at the University of Kentucky 
(Lexington, KY). 
As depicted in Figure 7, iRGD-conjugated nanoparticles were prepared by 
mixing 5 mg of the alkoxyamine-functionalized iRGD with 1 mg of Ac-Dex 
nanoparticles in 1 mL PBS. First, 5 mg of iRGD and 1 mg of nanoparticles was 
measured into 1 mL of PBS and was then sonicated in a water bath for 15 minutes. 
The samples were then put on a shaker at 37C and 100 rpm for 2 days. After 2 days, 
the samples were centrifuged at 12,000 rcf (10629 rpm) for 15 minutes and the 
supernatant was removed. The particles were washed twice with 1 mL fresh PBS and 
then resuspended using sonication. 100 µL/well of particle solution was added to each  
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Figure 7: Schematic depicting (i) the formation of Ac-Dex into Ac-Dex 
nanoparticles (NP), (ii) reducing end chain equilibrium between hemiacetal and 
straight-chain forms, and (iii) reaction of the reducing end aldehyde with 
alkoxyamine-conjugated iRGD. 
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well of a 96 well UV transparent plate and then 300 µL of 20 mg/mL of fluorescamine 
in acetone was added to each well make the total volume 400 µL. The fluorescamine 
reacts with primary amines in the iRGD to allow for the quantification of the amount 
of iRGD present in solution. The amount of iRGD conjugated to the nanoparticles was 
then evaluated using a fluorescence spectroscopy plate reader (Biotek Cytation3) at an 
excitation wavelength of 400 nm, emission wavelength of 460 nm, and gain of 100 
following one hour of incubation. 
To allow for the quantification of the amount of TAMRA-iRGD present on 
nanoparticles or cells, a calibration curve of TAMRA-iRGD was prepared in media 
without serum as seen in Figure A3. Concentrations of 0, 0.0005, 0.0025, 0.00375, 
0.005, 0.0125, 0.025, 0.0375, 0.05 mg/mL were prepared and 100 L of each 
concentration/solution was added to a 96 well plate. The fluorescence of the solutions 
was then read using an excitation wavelength of 540 nm and emission wavelength of 
585 nm (gain values of 50, 75, and 100) using the Biotek Cytation3 plate reader. 
To evaluate the affinity of TAMRA-iRGD nanoparticles to A549 lung 
adenocarcinoma cells, cells were seeded at 200,000 cells/mL (100 L/well) in 96 
wells plates and placed in an incubator for 24 hours. The cells were then exposed to 
different concentrations of TAMRA-iRGD in media including 0, 0.0005, 0.0025, 
0.00375, 0.005, 0.0125, 0.025, 0.0375, 0.05 mg/mL in serum-free media. At different 
time points (0, 0.5, 1, 2, 4, 7 and 24 hours), the area-average fluorescence of the 
samples was evaluated at an excitation wavelength of 540 nm and emission 
wavelength of 585nm with a gain of 100 using the Biotek Cytation3 plate reader. Prior 
  
42 
 
to analysis at each time point, the iRGD solution was removed from the wells and the 
cells were washed three times with PBS to remove any unbound iRGD. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
3.1 Characterization of Acetalated Dextran (Ac-Dex) 
Because of the significant differences in the rates of hydrolysis between the 
acyclic and cyclic acetals present on Ac-Dex, it is important to know the cyclic acetal 
coverage (CAC) of Ac-Dex to ensure that the degradation will be appropriate for the 
given application. The relative proportion of cyclic and acyclic acetals was determined 
by comparing the relative concentrations of acetone and methanol present during 
1
H-NMR analysis. This is possible since the hydrolysis of one acyclic acetal yields 
one molecule each of acetone and methanol, whereas the hydrolysis of one cyclic 
acetal yields only a single acetone molecule (Bachelder 2008). The CAC was then 
determined via the ratio of acetone to methanol by comparing the integration of the 
acetone peak (2.08 ppm) to the methanol peak (3.34 ppm) from 
1
H-NMR analysis. All 
integrations were normalized to the number of protons on each molecule. The 
calculation protocol for this method can be found in Appendix B.  
Analysis of Ac-Dex formed after a 5-minute reaction period was completed via 
1
H-NMR (see Figure 8). These results showed that the cyclic acetal coverage (CAC) 
of the fast degrading Ac-Dex was approximately 70%. In addition, the conversion of 
hydroxyl groups on the parent dextran to acetal group was at least 80% for all batches  
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Figure 8: Representative NMR spectra of acetalated dextran use for cyclic acetal 
coverage (CAC) calculations. 
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of Ac-Dex, indicating good coverage of acetals on the polymer backbone. The 
reported CAC value is appropriate for the desired application as Ac-Dex with this 
property is known to degrade with a few days (Bachelder 2008, Bachelder 2008, 
Meenach 2012), which is appropriate for the application of nanoparticles to tumors. 
 
3.2 Characterization of Drug-Loaded Ac-Dex Nanoparticles 
The size (diameter), polydispersity index (PDI), zeta potential, encapsulation 
efficiency, and drug loading of the nanoparticles was evaluated to show the feasibility 
and efficacy of using the emulsion/solvent evaporation method for the generation of 
chemotherapeutic nanoparticles. The size of both blank (no drug) and drug-loaded 
Ac-Dex nanoparticles was evaluated using dynamic light scattering (DLS) and the 
results are depicted in Table 4. The particles sizes range from 232 to 282 nm, which is 
suitable for nanoparticles used in the applications for the systemic delivery of 
nanoparticles and cancer treatment via tumor penetration and controlled delivery. 
Nanoparticle formulation and surface morphologies were visualized and analyzed 
via scanning electron microscopy (SEM) as seen in Figure 9. From these images it 
can be seen that the nanoparticles are smooth and spherical, which is appropriate for 
the indicated application. From these images it can be estimated that the diameters of 
both the blank and drug-loaded nanoparticles range from 200 to 300 nm, confirming 
the results gained from the DLS analysis. Finally, no differences were seen between 
systems with paclitaxel (PTX), imatinib mesylate (IM), and blank nanoparticles 
regarding their morphology, indicating the loading of the drug had little effect on these 
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Table 4: Physicochemical characterization results for blank and drug loaded 
nanoparticles including particle diameter, polydispersity index (PDI), zeta 
potential, encapsulation efficiency, and drug loading (g drug/mg nanoparticles). 
Data represents average values ± standard deviation for at least n = 3. 
 
Particle 
System 
Diameter 
(nm) 
PDI 
Zeta 
Potential 
(mV) 
Encapsulati
on 
Efficiency 
(%) 
Drug 
Loading (g 
drug/mg NP) 
0.1% PTX 232 ± 13 0.21 ±0.08 -0.40± 0.02 50 ± 17 0.5 ± 0.17 
10% Imatinib 282 ± 2 0.20 ± 0.02 -0.30 ± 0.03 14 ± 3 14 ± 3 
Blank 255 ± 25 0.19 ± 0.02 -2.43 ± 0.13 ---- ---- 
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Figure 9: Scanning electron micrographs of (a) 0.1% PTX, (b) 10% imatinib, and 
(c) blank acetalated dextran nanoparticles. 
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characteristics in comparison to blank particles without drug. 
The polydispersity index (PDI) values from Table 4 were approximately 0.20, 
indicating that the nanoparticles, regardless of the presence or type of drug in the 
nanoparticle systems. In addition, the zeta potential values of the nanoparticles ranged 
from -2.43 to -0.30 mV, indicating that the particle systems are all nearly neutral 
(Honary 2013, Honary 2013), with drug loading have no effect on this parameter. 
 The encapsulation efficiency of the nanoparticles was 50 % for 0.1% PTX 
nanoparticles and 14 % for 10% imatinib nanoparticles. This ultimately resulted in an 
actual drug loading of 0.52 g of PTX per mg of nanoparticles and 14 g of imatinib 
per mg of nanoparticles. Overall, these results indicate that both PTX and imatinib can 
be successfully loaded into Ac-Dex based nanoparticle systems using the 
emulsion/solvent evaporation particle formation method. In addition, it seems that 
there is some effect on drug loading due to either the type of drug loaded or the 
amount of drug loaded into the nanoparticle systems. This could be due to the 
hydrophobicity or lipophilicity of the drugs present in the nanoparticle systems.  
Figure 10 shows the results from differential scanning calorimetry (DSC) for the 
nanoparticle systems and raw components that made up the nanoparticles. While, the 
nanoparticles were evaluated a large temperature range, these results ultimately show 
that the nanoparticles are stable within a normal temperature range that nanoparticles 
would be exposed to during synthesis, storage, and administration (4 to 100°C). 
The release of paclitaxel and imatinib from acetalated dextran nanoparticles was 
evaluated over 48 hours as seen in Figure 11 (for paclitaxel nanoparticles) and Figure  
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Figure 10: Differential scanning calorimetry (DSC) thermogram of raw 
acetalated dextran (Ac-Dex), blank nanoparticles without drug (Blank NPs), raw 
paclitaxel (PTX), 0.1% PTX-loaded nanoparticles (0.1% PTX NPs), raw imatinib, 
and 10% imatinib-loaded nanoparticles (Imatinib NPS). 
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Figure 11: Amount of paclitaxel released versus time for 0.1% PTX 
nanoparticles. 
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Figure 12: Amount of imatinib released versus time for 10% IM nanoparticles. 
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12 (for imatinib nanoparticles). The release data shows that the drug-loaded 
nanoparticles (both PTX and imatinib) exhibited a burst release for the first two hours 
with 40 % released from PTX-loaded nanoparticles and 60 % released from IM-loaded 
nanoparticles during this time. Both systems then demonstrated controlled release after 
the first two hours and the final release for both systems was completed within 48 
hours. 
 Overall, these results demonstrate the feasibility in synthesizing PTX and 
IM-loaded nanoparticles with Ac-Dex as the polymer. The systems ultimately exhibit 
the desired morphological, size, charge, and shape necessary for systemic delivery to 
tumors and are stable at the desired working temperatures. Furthermore, the 
nanoparticles exhibit the ability to control the release of either PTX or IM for an 
extended amount of time, which can enhance the efficacy of using these systems in the 
treatment of lung cancer. 
 
3.3 In Vitro Biological Characterization 
The effect of raw paclitaxel, paclitaxel-loaded nanoparticles, and blank 
nanoparticles on the viability of A549 lung adenocarcinoma cells was evaluated 48 
hours after drug and/or nanoparticle exposure. The effect of raw PTX, PTX-loaded 
nanoparticles and raw Imatinib on A549 cells can be seen in Figure 13 and 14. For 
both the pure drug and PTX nanoparticles, the cell viability decreased with increasing 
drug concentration as expected. Furthermore, the relative viability of A549 cells 
exposed to PTX-loaded nanoparticles was lower than that for pure PTX. This  
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Figure 13: Dose-response curve for A549 cells exposed to PTX and 0.1% 
PTX-loaded nanoparticles. 
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Figure 14: Dose-response curve for A549 cells exposed to Imatinib. 
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indicated that it takes a lower concentration of drug in the nanoparticles to kill the 
same number of cells as compared to the pure PTX. This is also indicated by the IC50 
values, were the IC50 value for raw PTX was 0.2299 µM and for PTX NPs was 
0.0695 µM. This ultimately indicates that the PTX-loaded nanoparticles are more 
effective in killing lung cancer cells than pure PTX, even without iRGD conjugation. 
And the IC50 of raw Imatinib was 4.0993 µM. 
The effect of blank nanoparticles on A549 cells was also evaluated. The amount 
of nanoparticles loaded into media for exposure to the cells was determined by using 
the largest mass of nanoparticles needed for the highest concentration of PTX. The 
relative viability of cells exposed to blank nanoparticles was 96 %, indicating that the 
nanoparticle exert minimal to no cytotoxic effects on A549 cells. This, in turn, 
demonstrates that they should be safe for administration of anticancer therapeutics. 
The potential for Ac-Dex nanoparticles to be uptaken into A549 cells was 
evaluated. For these initial studies, FITC-loaded nanoparticles with no drug were 
evaluated by exposing the cells to nanoparticles for 5 hours. Figure 14 shows that 
after 5 hours the A549 cells exhibited very minimal uptake of FITC-loaded 
nanoparticles. This could potentially be attributed to the short exposure time or the 
lack of peptide targeting for these nanoparticles since no iRGD was conjugated onto 
the nanoparticle surfaces. 
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Figure 15: Representative fluorescent image from uptake studies where A549 
lung adenocarcinoma cells were exposed to FITC-loaded nanoparticles for 5 
hours. The blue fluorescence indicates the cell nuclei, red indicates cellular 
lysosomes, and green indicates the uptaken nanoparticles. 
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Figure 16: Bright field images of three-dimensional multicellular spheroids comprised 
of A549 lung adenocarcinoma cells via centrifugation. The scale bar for 0 hour is 10 
m whereas the scale bar for Days 1 through 5 is 100 m. 
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3.4 Three-Dimensional Multicellular Spheroid Evaluation 
Three-dimensional (3D) multicellular spheroids (MCS) comprised of A549 lung 
cancer cells were successfully formed using a modified centrifugation technique. In 
this technique, cells in a small amount of collagen were seeded into non-adherent 
round bottom 96 well plates followed by mild centrifugation. As shown in Figure 15, 
immediately after centrifugation (0 hour), the cells formed a two-dimensional (2D) 
confluent monolayer on the bottom of the round bottom well plates. Within 24 hours 
(Day 1 image) 3D MCS have formed and continue to grow with time. These spheroids 
show spherical morphology with a high density of cells within their structure.  
The size of the spheroids was analyzed by using the brightfield images and 
ImageJ software. As seen in Figure 16, the size of the spheroids increased with 
culture time and the spheroids reached a diameter of approximately 560 m after 5 
days. Overall, these results indicate the successful formation of A549 multicellular 
spheroids where these systems will be used in future studies relating the 
tumor-penetrating nanoparticles. 
 
3.5 iRGD-Nanoparticle Conjugation and Affinity to A549 Cells 
The amount of iRGD capable of conjugating to acetalated dextran nanoparticles 
was determined using the fluorescamine assay. These results indicated that 
approximately 5.618 x 10
4
 molecules of iRGD were conjugated to each nanoparticle 
and the iRGD coverage is 0.287 iRGD/nm
2
. Overall, these results show that acetalated 
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dextran nanoparticles can be produced that will be capable of tumor homing and 
penetration through the iRGD tumor penetrating mechanism. 
The affinity of iRGD to A549 cells was evaluated by exposing these cells to 
differing concentrations of TAMRA-conjugated iRGD for different times (up to 24 
hours). These results are indicated in Figure 17, which showed that iRGD interacts 
with and likely penetrates A549 lung adenocarcinoma cells. In this figure, 
fluorescence intensity of the TAMRA-iRGD attached to the cells is compared to the 
iRGD concentration and exposure time. After 3 hours, the fluorescence intensity of the 
samples was the highest regardless of iRGD solution concentration. This indicates that 
this is the optimal time period for A549 cells to interact with and uptake iRGD, which 
will be useful in designing future in vitro experiments with respect to exposure time. 
Overall, the fluorescence intensity of the samples increased with increasing 
TAMRA-iRGD concentration. This is expected because there is a linear relationship 
between the concentrations of iRGD in serum-free media with respect to fluorescence 
intensity as shown by the calibration curve in Figure A3 (see Appendix A). Overall, 
these studies show the feasibility in using iRGD-conjugated nanoparticles to target 
A549 lung adenocarcinoma cells for the enhanced treatment of lung cancer. 
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Figure 17: Diameter of three-dimensional multicellular spheroids with respect to 
time. The diameter of the spheroids was evaluated using brightfield images and 
ImageJ software. 
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Figure 18: Results indicating the iRGD affinity to A549 lung adenocarcinoma 
cells. A549 cells were exposed to different concentrations of TAMRA-iRGD for 
up to 24 hours. The fluorescence intensity of the TAMRA-iRGD was then 
evaluated.
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CHAPTER 4 
CONCLUSIONS AND FUTURE WORK 
4.1 Conclusions 
Two kinds of drug-loaded nanoparticles were successfully synthesized using the 
polymer acetalated dextran in this study. These systems were comprised of 0.1% 
paclitaxel (PTX) and 10% imatinib-loaded nanoparticles. Overall, their physical and 
chemical characteristics have been evaluated. The developed systems exhibited 
favorable size (diameter), polydispersity in relation to size, and zeta potential to allow 
for their use in the systemic delivery of anticancer therapeutics. Both the encapsulation 
efficiency and drug loading were also favorable for the application of these 
nanoparticles for potential the treatment of lung cancer.  
In vitro cell studies showed that drug-loaded nanoparticles increases the efficacy 
of chemotherapeutic drugs (in particular paclitaxel) for A549 lung carcinoma cells. It 
is possible that chemotherapeutic drug-loaded Ac-Dex nanoparticles could be applied 
in vivo to treat non-small cell lung cancer while reducing the toxic side effects of the 
free drug normally delivered systemically.  
For this application, drug-loaded Ac-Dex nanoparticles could potentially be 
actively targeted to non-small cell lung cancer tumors and vasculature and then 
penetrate into the tumors cells with the help of tumor-penetrating peptide, iRGD. This 
intracellular environment would then trigger the intracellular burst release of the drug 
payload due to the acid-sensitivity of the Ac-Dex polymer with minimal drug released 
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in extracellular pH-neutral environments. The results of the described study indicate 
that iRGD can be successfully conjugated to Ac-Dex nanoparticles and that iRGD also 
shows affinity for A549 cells that are known to overexpress integrins that allow active 
targeting of the nanoparticle systems. Overall, these drug-loaded nanoparticles may 
have the ability to treat non-small lung cancer in addition to numerous other types of 
cancer.  
 
4.2 Future Work 
 The work described in this thesis is hopefully just the beginning regarding the 
investigation of tandem delivery of agents using nanoparticles system for the 
treatment of non-small cell lung cancer. Future work to build upon this project may 
include, but is not limited to: 
 Optimization of nanoparticles size and encapsulation efficiency to achieve a 
better effect during in vitro studies.  
 Investigation of the methods of loading two drugs into one nanoparticle 
system to reduce side effects and allow for dual delivery. 
 Optimizing and evaluating the conjugation of iRGD onto blank and 
drug-loaded nanoparticle systems. 
 Investigation into the ability of iRGD-conjugated nanoparticles to increase 
the efficacy of non-iRGD nanoparticles against A549 cells on both 2D 
monolayer and 3D spheroid cultures. 
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 Evaluating the ability of iRGD-conjugated nanoparticles to penetrate 3D 
multicellular spheroids. 
 Evaluating the systemic efficacy of iRGD-conjugated Ac-Dex nanoparticles 
in vivo in both non-small cell lung cancer cells and tissues. 
 Incorporation of iRGD-conjugated, drug-loaded nanoparticles with radiation 
treatment to increase their therapeutic effect. 
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APPENDIX A 
CALIBRATION CURVES 
 
As described in Chapter 2 (Materials and Methods), calibration curves for 
paclitaxel (PTX) and imatinib mesylate (IM) were generating using ultra performance 
liquid chromatography (UPLC). As seen in Figure A1, a plot of the peak area due to 
the detection of PTX compared to its concentration was generated. This figure shows a 
lower detection limit of 10 g/ml and upper detection limit of 80 g/ml in the mobile 
phase for PTX. The R-squared value of 0.9999 shows very good fit for the described 
data. A plot of peak area due to the detection of IM compared to its concentration can 
be found in Figure A2. This figure shows a lower detection limit of 10 g/ml and 
upper detection limit of 100 g/ml for imatinib mesylate in mobile phase with a 
favorable R-squared value of 0.9944. 
TAMRA-iRGD calibration curves were generated using fluorescence detection of 
a plate reader as described in Chapter 2 (Materials and Methods) as seen in Figure 
A3. For this detection, the lower limit was 0.0005 g/ml and the upper limit was 0.05 
g/ml with a favorable R-squared value of 0.9. Finally an iRGD-fluorescamine 
calibration curve was generated using fluorescence microscopy. As seen in Figure A4, 
the lower limit was 0.1 mg/ml iRGD and the upper limit was 0.5 mg/ml with a 
favorable R-squared value of 0.9716. 
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Figure 19: Calibration curve for paclitaxel (PTX) generated using ultra 
performance liquid chromatography (UPLC). 
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Figure 20: Calibration curve for imatinib mesylate (IM) generated using ultra 
performance liquid chromatography (UPLC). 
 
 
y = 8761.4x - 47913 
R² = 0.9944 
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
0 50 100 150
P
ea
k
 a
re
a 
Imatinib Mesylate Concentration (μg/ml) 
  
68 
 
 
 
 
 
 
 
Figure 21: Calibration curve for TAMRA-iRGD as generated using fluorescence 
spectroscopy (plate reader). 
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APPENDIX B 
1
H-NMR CALCULATIONS FOR AC-DEX 
 
The cyclic acetal coverage (CAC) of Ac-Dex was determined using 
1
H-NMR as 
described in Section 2.2 (Synthesis and Characterization of Acetalated Dextran 
(Ac-Dex)). Using the software available on the equipment, the areas of characteristic 
peaks of several compounds were calculated. These included the peak areas for the 
hydrogen rings present in dextran (3.4 to 4.0 ppm, three peaks total), methanol (3.36 
ppm), and acetone (2.08 ppm). First, a normalization factor was calculated for the 
dextran peaks: 
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 (𝑁𝐹) =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐷𝑒𝑥𝑡𝑟𝑎𝑛 𝑃𝑒𝑎𝑘𝑠
2
 
 
where 2 is the number of protons available on each molecule. Next the amount of 
methanol (MeOH) and acetone (Ace) present in the samples was calculated using the 
following equations: 
 
𝑀𝑒𝑂𝐻 =  
𝑀𝑒𝑡ℎ𝑎𝑛𝑜𝑙 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
3 ∗ 𝑁𝐹
 
 
𝐴𝑐𝑒 =  
𝐴𝑐𝑒𝑡𝑜𝑛𝑒 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
6 ∗ 𝑁𝐹
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where NF is the normalization factor. NF was multiplied by 3 for the methanol 
samples and by 6 for the acetone samples owing to the number of hydrogen molecules 
present in these compounds. Finally, the cyclic acetal coverage (CAC) was calculated 
to be: 
 
𝐶𝐴𝐶 = (𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻) 𝑥 100% 
 
The extent of -OH hydrolysis was also calculated via 
1
H-NMR analysis: 
𝐶𝑦𝑐𝑙𝑖𝑐 𝑎𝑐𝑒𝑡𝑎𝑙 𝑝𝑒𝑟 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻 
𝐴𝑐𝑦𝑐𝑙𝑖𝑐 𝑎𝑐𝑒𝑡𝑎𝑙 𝑝𝑒𝑟 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 𝑀𝑒𝑂𝐻 
Two of the three and one of three hydroxyls on each glucose repeat unit can be 
used to form a single cyclic acetal and acyclic acetal, respectively. The number of -OH 
groups converted per glucose (-OH Conv) was calculated as: 
 
−𝑂𝐻 𝐶𝑜𝑛𝑣 = 𝑀𝑒𝑂𝐻 + 2(𝐴𝑐𝑒 − 𝑀𝑒𝑂𝐻) 
 
The percent acetalation ratio was then calculated as: 
 
% 𝐴𝑐𝑒𝑡𝑎𝑙𝑎𝑡𝑖𝑜𝑛 =  
−𝑂𝐻 𝐶𝑜𝑛𝑣
3
 𝑥 100% 
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APPENDIX C 
 
CALCULATIONS FOR DETERMINING IRGD COVERAGE 
 
 The number of iRGD molecules present on the surface of the Ac-Dex 
nanoparticles was determined using the fluorescamine assay. Fluorescamine reacts 
with primary amines on iRGD to allow for quantification of the amount of iRGD 
present in solution. As seen in Figure 22, there is a linear relationship between the 
fluorescence intensity of fluorescamine and the concentration of iRGD in PBS. 
Therefore, the amount of iRGD present on nanoparticles and the iRGD coverage per 
nanoparticle can be calculated from the following calculations. From the 
fluorescamine assay, the mass of iRGD present in the sample (miRGD) was 0.623 mg. 
From this value, the molecules of iRGD per sample was calculated as: 
 
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑜𝑓 𝑖𝑅𝐺𝐷 =  
𝑚𝑖𝑅𝐺𝐷 ∙ 𝑁𝐴
𝑀𝑊
 
 
where MW is the molecular weight of iRGD (1569.71 g/moles) and NA is 
Avogadro’s number (6.02214 x 1023 molecules/mole). The molecules of iRGD in 1 ml 
of solution was determined to be 3.969 x 10
16
 molecules. The number of nanoparticles 
present in each sample was determined from the nanoparticle volume, density, and 
mass per sample. The mass of an individual nanoparticle is calculated as: 
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𝑀𝑎𝑠𝑠 𝑜𝑓 𝑠𝑖𝑛𝑔𝑙𝑒 𝑁𝑃 (𝑚𝑛) =  𝑉𝜌 
where V is the volume of a 255 nm nanoparticle (1.413 x 10
7
 nm
3
) and ρ is the 
density of the nanoparticle (1 g/cm
3
), which is the density of most polymers. This 
gives a mass of a single nanoparticle to be 1.413 x 10
-11
 mg. The number of 
nanoparticles in a sample was then calculated from the total mass of nanoparticle (mT 
= 5 mg) and mass of a single nanoparticle: 
 
# 𝑜𝑓 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 =  
𝑚𝑇
𝑚𝑛
 
 
where the total number of nanoparticles per sample was 7.065 x 10
11
. The number 
of iRGD present on each nanoparticle was then calculated from the number of 
nanoparticle (mn) and number of iRGD molecules: 
 
𝑖𝑅𝐺𝐷 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑝𝑒𝑟 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =  
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑜𝑓 𝑖𝑅𝐺𝐷
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 
 
The number of iRGD molecules per nanoparticles was calculated to be 5.618 x 
10
4
. The iRGD coverage was then calculated form the number of iRGD molecules per 
nanoparticle and surface area of a single nanoparticle (A = 1.96 x 10
5
 nm
2
): 
 
𝑖𝑅𝐺𝐷 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 =  
𝑖𝑅𝐺𝐷 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑝𝑒𝑟 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝐴
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It was determined that there are 0.287 molecules of iRGD per nm
2
 of particle 
area. 
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Figure 22: iRGD calibration curve as generated using fluorescence spectroscopy 
(plate reader). 
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